Company:  MALLINCKRODT PLC (MNK)
Form Type:  8-K
Filing Date:  2/13/2018 
CIK:  0001567892 
Address:  3 LOTUS PARK, THE CAUSEWAY
STAINES-UPON-THAMES
 
City, State, Zip:  SURREY,  TW18 3AG 
Telephone:  44-017-8463-6700 
Fiscal Year:  12/29 
Last Trade
Last Trade: 
$16.17  
Change: 
-0.54 (-3.23%)  
Trade Time: 
04:02 PM EST  
Market Cap: 
$1.54B
Trade MNK now with 

© 2018  
Description of Business
Mallinckrodt plc and its subsidiaries (collectively, "Mallinckrodt" or "the Company"), is a global specialty biopharmaceutical and nuclear imaging business that develops, manufactures, markets and distributes specialty pharmaceutical and biopharmaceutical products and nuclear imaging agents. Therapeutic areas of focus include autoimmune and rare disease specialty areas (including neurology, rheumatology, nephrology and pulmonology); immunotherapy and neonatal respiratory critical care therapies; pain management; and central nervous system drugs. The Company also supports the diagnosis of disease with nuclear medicine imaging agents. The Company believes its experience in the acquisition and management of highly regulated raw materials; deep regulatory expertise; and specialized chemistry, formulation and manufacturing capabilities have created compelling competitive advantages that it anticipates will sustain future revenue growth.
Register and access this filing in:     
  FORM 8-K
    SECTION 1 BUSINESS AND OPERATIONS
      Item 1.01. Entry into a Material Definitive Agreement.
    SECTION 2 FINANCIAL INFORMATION
      Item 2.01. Completion of Acquisition or Disposition of Assets.
      Item 2.03. Creation of a Direct Financial Obligation or an ...
    SECTION 7 REGULATION FD
      Item 7.01. Regulation FD Disclosure.
    SECTION 9 FINANCIAL STATEMENTS AND EXHIBITS
      Item 9.01. Financial Statements and Exhibits.
    Exhibit Index
    SIGNATURES